Transcript The Molecular Biomarkers in Cancer (MBiC) slide presentation is
Slide 1
Disclosure/Disclaimer
The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an
independent educational program, and no CME credits will be provided.
This program is not intended to promote any cancer agent
or class approved by the FDA/EMA or currently
under clinical development.
The contents of this slide presentation are owned solely
by Genentech; any unauthorized uses are prohibited.
This program is presented on behalf of Genentech and the
information presented is consistent with FDA guidelines.
The following slides are selected samples from a complete presentation.
They are for educational purposes only.
BIO0002078200
2013 Genentech USA, Inc. All rights reserved.
1
Slide 2
Notes
Types of cancer biomarkers and their utility
Screening
Screening
diagnostic
Monitor
progression
Resistance
Disease burden
events
molecular
detection
clinical
detection
intervention
treatment
Reference:
Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and
treatment selection. Nat Rev Cancer. 2005;5:845-856.
Ludwig JA, Weinstein JN. Nat Rev Cancer. 2005;5:845-856. Vogelstein B, et al. Nat Med. 2004;10:789-799.
Cost / irreversibility
Prognostic
Predictive
Biomarkers can play a significant role during the clinical
Earliest
management
of cancer. Earliest
Initiating
Typical
Second-line
© 2013 Genentech USA, Inc. MBiC Program
2
Slide 3
Notes
Methods of biomarker detection
Cancer
Normal
cDNAcells
microarrays
providecells
a powerful tool for studying
differential changes in gene expression patterns across a
variety of tumor samples.
Isolate
mRNAs
Reference:
Tumor
gene
Yang YH, Speed T. Design issues for cDNA microarray experiments.
Nat Rev
Genet.Make
2002;3:579-588.
red and green
expression
fluorescent cDNAs
Hybridization
Microarrays
Yang YH, Speed T. Nat Rev Genet. 2002;3:579-588.
Analyze data
© 2013 Genentech USA, Inc. MBiC Program
3
Slide 4
Notes
Measuring the risk of metastatic potential
•
•
A simultaneous measurement of 70 cancer-related genes in tumor
specimens by microarray technology
– Evaluates genes involved in cell-cycle regulation, angiogenesis, invasion,
signal transduction, and migration
An expression signature determined through the 70-gene
Test measures
the 10-year
of metastasis
for women
with lymphmicroarray
test can risk
be used
to stratify patients
into highnode–negative,
ER–positive,
and low-risk
groups. or ER–negative disease
Potential markers for metastasis
Cancer
Reference:
Ma L, Weinberg RA. Micromanagers of malignancy: role ofLow
microRNAs
risk in
Patient
A
regulating metastasis. Trends Genet. 2008;24:448-456.
No metastatic
potential;
conservative
therapy possible
Cancer biopsy
High risk
Cancer Patient B
Cancer biopsy
ER=estrogen receptor.
van't Veer LJ, Bernards R. Nature. 2008;452:564-570. Ma L, Weinberg RA. Trends Genet. 2008;24:448-456.
Adapted from Weinberg. Sci Am. 1996;275:62-70.
Metastatic
potential;
aggressive
therapy needed
© 2013 Genentech USA, Inc. MBiC Program
4
Disclosure/Disclaimer
The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an
independent educational program, and no CME credits will be provided.
This program is not intended to promote any cancer agent
or class approved by the FDA/EMA or currently
under clinical development.
The contents of this slide presentation are owned solely
by Genentech; any unauthorized uses are prohibited.
This program is presented on behalf of Genentech and the
information presented is consistent with FDA guidelines.
The following slides are selected samples from a complete presentation.
They are for educational purposes only.
BIO0002078200
2013 Genentech USA, Inc. All rights reserved.
1
Slide 2
Notes
Types of cancer biomarkers and their utility
Screening
Screening
diagnostic
Monitor
progression
Resistance
Disease burden
events
molecular
detection
clinical
detection
intervention
treatment
Reference:
Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and
treatment selection. Nat Rev Cancer. 2005;5:845-856.
Ludwig JA, Weinstein JN. Nat Rev Cancer. 2005;5:845-856. Vogelstein B, et al. Nat Med. 2004;10:789-799.
Cost / irreversibility
Prognostic
Predictive
Biomarkers can play a significant role during the clinical
Earliest
management
of cancer. Earliest
Initiating
Typical
Second-line
© 2013 Genentech USA, Inc. MBiC Program
2
Slide 3
Notes
Methods of biomarker detection
Cancer
Normal
cDNAcells
microarrays
providecells
a powerful tool for studying
differential changes in gene expression patterns across a
variety of tumor samples.
Isolate
mRNAs
Reference:
Tumor
gene
Yang YH, Speed T. Design issues for cDNA microarray experiments.
Nat Rev
Genet.Make
2002;3:579-588.
red and green
expression
fluorescent cDNAs
Hybridization
Microarrays
Yang YH, Speed T. Nat Rev Genet. 2002;3:579-588.
Analyze data
© 2013 Genentech USA, Inc. MBiC Program
3
Slide 4
Notes
Measuring the risk of metastatic potential
•
•
A simultaneous measurement of 70 cancer-related genes in tumor
specimens by microarray technology
– Evaluates genes involved in cell-cycle regulation, angiogenesis, invasion,
signal transduction, and migration
An expression signature determined through the 70-gene
Test measures
the 10-year
of metastasis
for women
with lymphmicroarray
test can risk
be used
to stratify patients
into highnode–negative,
ER–positive,
and low-risk
groups. or ER–negative disease
Potential markers for metastasis
Cancer
Reference:
Ma L, Weinberg RA. Micromanagers of malignancy: role ofLow
microRNAs
risk in
Patient
A
regulating metastasis. Trends Genet. 2008;24:448-456.
No metastatic
potential;
conservative
therapy possible
Cancer biopsy
High risk
Cancer Patient B
Cancer biopsy
ER=estrogen receptor.
van't Veer LJ, Bernards R. Nature. 2008;452:564-570. Ma L, Weinberg RA. Trends Genet. 2008;24:448-456.
Adapted from Weinberg. Sci Am. 1996;275:62-70.
Metastatic
potential;
aggressive
therapy needed
© 2013 Genentech USA, Inc. MBiC Program
4